Vigonvita seeks US$100M in Hong Kong IPO for COVID-19 drug expansion. It has commercialized COVID-19 drugs in the past and is looking to expand indications.
What is covered in the Full Insight:
Introduction to Vigonvita
Core Drug Candidates Overview
Clinical Development Progress
Management and Pre-IPO Investors
Competitive Landscape
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.